China National Pharmaceutical Holdings (01099.HK): China National Pharmaceutical announced its performance quick report, with net profit attributable to the parent increasing by 76.8% to 1.136 billion yuan.

NightAirdropper · 2026-03-18T06:57:18+00:00

China Pharma Holdings' 2025 Performance Flash Report shows operating revenue of 73.416 billion yuan, down 1.29% year-over-year; net profit of 1.136 billion yuan, up 76.80% year-over-year. The profit growth was mainly driven by decreased goodwill and intangible asset impairment provisions and reduced costs.

NightAirdropper

2026-03-18 06:57:18

Abstract generation in progress

Gelonghui, March 18 — China National Pharmaceutical Group (01099.HK) announced that China National Pharmaceutical Group Co., Ltd. (000028.SZ) released its 2025 annual performance forecast. According to preliminary calculations, during the reporting period, China National Pharmaceutical Group Co., Ltd. achieved operating revenue of 73.416 billion yuan (RMB), a decrease of 1.29% year-on-year; operating profit of 1.513 billion yuan, a year-on-year increase of 163.80%; total profit of 1.509 billion yuan, a year-on-year increase of 162.22%; net profit attributable to shareholders of China National Pharmaceutical Group Co., Ltd. of 1.136 billion yuan, a year-on-year increase of 76.80%, with basic earnings per share increasing by 77.39% year-on-year, and the weighted average return on net assets rising by 2.59 percentage points. The profit growth for China National Pharmaceutical Group Co., Ltd. during this period was mainly due to a reduction of 686 million yuan in asset impairment provisions for goodwill and intangible assets, combined with decreased fixed costs such as labor and rent resulting from store adjustments.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.